Chemomab Therapeutics Ltd. announced that Chemomab co-founder, Chief Executive Officer and Chief Scientific Officer Adi Mor, PhD, will discuss the CM-101 clinical program in primary sclerosing cholangitis (PSC) at the 2023 Roth MKM Healthcare Opportunities Conference on October 12, 2023. The conference is being held at the Yale Club in New York City. Dr. Mor will give a live presentation at 12:00 noon ET and company executives will participate in one-on-one meetings with investors.

Chemomab's first-in-class monoclonal antibody CM-101 neutralizes CCL24, a novel target that has been shown to play a central role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the Phase 2 SPRING trial for the treatment of PSC, with topline data expected in the second half of 2024. PSC is a potentially lethal condition that lacks any FDA-approved therapies and frequently requires liver transplant.

Unlike the other drugs in clinical development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation. In extensive preclinical and early clinical studies, this distinctive, multifaceted approach has been shown to inhibit fibrogenesis and interfere with the core pathways that result in the liver damage associated with PSC. Earlier this year, Chemomab reported positive results from a Phase 2a liver fibrosis trial in patients with nonalcoholic steatohepatitis (NASH).

A majority of patients treated with CM-101 demonstrated improvements in multiple biomarkers associated with fibrosis and inflammation. A higher percentage of patients responding to treatment with CM-101 had improvements in Enhanced Liver Fibrosis (ELF) scores, liver stiffness as measured by transient elastography, and PRO-C3 levels compared to placebo. The ELF score, liver stiffness as measured by transient elastography and PRO-C3, a marker of collagen III formation, have all been identified as prognostic markers and independent predictors of transplant-free survival and improved patient outcomes in PSC.

These results suggest that CM-101 possesses anti-fibrotic properties in the liver that may also be relevant in PSC, and Chemomab views these data as promising for a potentially successful translation to the treatment of PSC. The company's ongoing PSC Phase 2 SPRING trial is evaluating two dose cohorts that are intended to provide high exposure to CM-101 (10 and 20mg/kg intravenously administered, compared to 5mg/kg via subcutaneous injection in the liver fibrosis/NASH trial), as well as an open-label extension providing for longer-term evaluation of the effects of CM-101 treatment for up to 48 weeks, thereby enhancing the opportunity for a more comprehensive assessment of CM-101's therapeutic potential in PSC.